Amgen's obesity drug AMG 513 completes Phase 1 trial

Amgen Inc (AMGN) has completed Phase 1 of its clinical trial for AMG 513, a new obesity treatment. The study, designed as a randomized, double-blind, placebo-controlled trial, aimed to assess the safety, tolerability, and early efficacy of the injectable drug in participants with obesity or overweight. The trial employed a sequential approach, testing single and multiple ascending doses to determine optimal dosing levels and monitor the drug's impact on key health markers.

The Phase 1 trial, first submitted on September 3, 2024, has now reached its primary completion date, though the exact date was not specified. The most recent update was posted on October 5, 2026, indicating that the trial has moved into the data analysis phase. While no results have been released yet, the update suggests that Amgen is reviewing the data, which could soon inform a decision on advancing to Phase 2 testing.

For investors, the completion of this Phase 1 trial adds potential value to Amgen's pipeline, particularly in the competitive obesity drug market currently dominated by Novo Nordisk and Eli Lilly. A successful outcome could position Amgen as a strong challenger in this high-growth sector, diversifying its revenue beyond its existing oncology and inflammation treatments. However, the company's future success will depend on the results of later-phase trials.

The study details and future updates will be available on the ClinicalTrials portal as they become available.